Related Experiment Videos
[Hepatitis B and C in intravenous drug abusers in Switzerland]
1Institut für Suchtforschung, Zürich.
Insights
Hepatitis B and C infections remain high among intravenous drug users, with many unaware of risks from shared needles and utensils. Improved prevention strategies and medical advice are crucial for reducing transmission.
Area of Science:
- Hepatology
- Infectious Diseases
- Public Health
Context:
- High prevalence of hepatitis B and C among intravenous drug users (IDUs).
- Intravenous drug use remains a significant risk factor for viral hepatitis transmission.
- Existing HIV prevention measures have not effectively curbed hepatitis B and C spread in this population.
Purpose:
- To highlight the urgent need for optimizing prevention strategies for hepatitis B and C among IDUs.
- To emphasize the importance of improving harm reduction measures and individual protective behaviors.
- To underscore the role of medical advice and education in mitigating infection risks.
Summary:
- Despite decades of intravenous drug use, hepatitis B and C infections persist at high rates.
- Many IDUs are inadequately informed about transmission risks associated with shared injection equipment.
- Low vaccination rates against hepatitis B are observed in this vulnerable group.
Impact:
- Optimizing structural interventions and harm reduction programs is essential.
- Enhanced medical counseling on safe practices can improve individual protective behaviors.
- Development of sustainable, targeted intervention programs is necessary to combat viral hepatitis in IDUs.
Abstract:
Since the 1980s hepatitis B and C have spread greatly among intravenous drug consumers. This shows up today in a high prevalence for both pathogens. It is striking that many patients who have only consumed drugs intravenously for a few years have already been infected with hepatitis B or C. The clear reduction in the spread of HIV within the drug-using community achieved by targeted measures during recent years has not had a similar impact on hepatitis B and C. Given this background, optimising preventive efforts among intravenous drug users is of great importance. Structural steps for therapy and damage-reduction should be optimised even more. Moreover, individual protective behaviour among patients should be improved. Medical advice and care is of great importance in this case. New studies show that many intravenous drug consumers are insufficiently informed on the risks of infection from shared use of injection utensils (spoons, filters, etc.) or drug sharing with used needles. Moreover, many drug consumers are not vaccinated against hepatitis B. Medical advice on protective behaviour should address these problems more directly. In the future, other sustainable intervention programmes based on this approach will need to be developed.